EUVIMEDEUVIMED entdecken
Crossref

Treatment in Clinical Trials Could Mitigate Socioeconomic and Racial Disparities in Acute Myeloid Leukemia

Mahesh Swaminathan, Hussein A Abbas, Michael Roth, Michelle A T Hildebrandt, Warren Fingrut, Tapan Kadia, Naval Daver, Courtney DiNardo, Gautam Borthakur, Elias Jabbour, Naveen Pemmaraju, Yesid Alvarado und 14 weitere

Clinical Lymphoma Myeloma and Leukemia · 2026

DOI: 10.1016/j.clml.2026.06.011 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Lymphoma Myeloma and Leukemia, 2026. Verfasst von Mahesh Swaminathan und 25 weiteren Autor:innen. Beteiligte Einrichtung: Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX. Electronic address: mswaminathan@mdanderson.org. Hauptthemen laut MEDLINE: Healthcare Disparities, Leukemia, Myeloid, Acute. Die Arbeit nennt 30 Literaturangaben. Gefördert von: The University of Texas MD Anderson Cancer Center.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Disparities in acute myeloid leukemia (AML) outcomes due to nonbiological factors, including socioeconomic (SE) status and race/ethnicity, have been observed in population-based studies. However, inconsistent assessment of SE status limits translation to clinical practice. OBJECTIVE: To evaluate the impact of neighborhood disadvantage status and race/ethnicity on AML outcomes. METHODS: Adult patients with newly diagnosed untreated AML, self-reported race/ethnicity, and available Area Deprivation Index (ADI) based on zip code at diagnosis were included. Primary outcome was overall survival (OS). Multivariable Cox regression analyzed factors associated with OS. RESULTS: Of 2442 patients, 2032 (83%) were non-Hispanic White, 202 (8%) were non-Hispanic Black, 109 (5%) were Hispanic, and 99 (4%) were Asian. Median ADI rank was 53 (IQR, 32-73). No differences in clinical trial participation across racial/ethnic groups were observed. Stem cell transplant rates were lower in more disadvantaged neighborhoods (higher ADI ranks, ≥ 53: 16% vs. 20%, P = .007). In multivariable analysis, clinical trial participation (HR 0.72, [95% CI, 0.63-0.81], P < .001) and transplant (HR 0.43, [95% CI, 0.36-0.51], P < .001) were associated with improved OS. Neither ADI rank nor race/ethnicity affected OS. CONCLUSIONS AND RELEVANCE: In a large academic center, neighborhood disadvantage and race/ethnicity did not affect AML outcomes. Equitable access to clinical trials and novel therapies appears to mitigate SE and racial/ethnic disparities. These findings suggest academic centers can serve as models for reducing inequities through policy and clinical interventions. Prospective multicenter studies are needed to validate these findings.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Healthcare DisparitiesLeukemia, Myeloid, AcuteAdultAgedFemaleHumansMaleMiddle AgedClinical Trials as TopicRacial GroupsSocioeconomic Disparities in HealthSocioeconomic FactorsWhiteBlack or African AmericanAsianHispanic or Latino

Stichwörter der Autor:innen

Area deprivation indexFrontline treatmentNeighborhood disadvantageRacial/ethnic disparityStem cell transplant

Autor:innen und Institutionen

  • Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX. Electronic address: mswaminathan@mdanderson.org.
  • Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX.
  • Department of Pediatrics, The University of Texas MD Anderson Cancer Center, Houston, TX.
  • Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX.
  • Department of Stem Cell Transplantation, The University of Texas MD Anderson Cancer Center, Houston, TX.
  • Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX.

Förderung

  • The University of Texas MD Anderson Cancer Center

Zitieren

APA

Swaminathan, M., Abbas, H. A., Roth, M., Hildebrandt, M. A. T., Fingrut, W., Kadia, T., Daver, N., DiNardo, C., Borthakur, G., Jabbour, E., Pemmaraju, N., Alvarado, Y., Ohanian, M., Jain, N., Short, N., Bose, P., Takahashi, K., Pierce, S., Hwang, H., …, & Ravandi, F. (2026). Treatment in Clinical Trials Could Mitigate Socioeconomic and Racial Disparities in Acute Myeloid Leukemia. Clinical Lymphoma Myeloma and Leukemia. https://doi.org/10.1016/j.clml.2026.06.011

Vancouver

Swaminathan M, Abbas HA, Roth M, Hildebrandt MAT, Fingrut W, Kadia T, et al. Treatment in Clinical Trials Could Mitigate Socioeconomic and Racial Disparities in Acute Myeloid Leukemia. Clinical Lymphoma Myeloma and Leukemia. 2026. doi:10.1016/j.clml.2026.06.011

BibTeX
@article{Swaminathan2026,
  author = {Swaminathan, Mahesh and Abbas, Hussein A and Roth, Michael and Hildebrandt, Michelle A T and Fingrut, Warren and Kadia, Tapan and Daver, Naval and DiNardo, Courtney and Borthakur, Gautam and Jabbour, Elias and Pemmaraju, Naveen and Alvarado, Yesid and Ohanian, Maro and Jain, Nitin and Short, Nicholas and Bose, Prithviraj and Takahashi, Koichi and Pierce, Sherry and Hwang, Hyunsoo and Huang, Xuelin and Edelkamp, Paul and Kebriaei, Partow and Popat, Uday and Shpall, Elizabeth and Garcia-Manero, Guillermo and Ravandi, Farhad},
  title = {Treatment in Clinical Trials Could Mitigate Socioeconomic and Racial Disparities in Acute Myeloid Leukemia},
  journal = {Clinical Lymphoma Myeloma and Leukemia},
  year = {2026},
  doi = {10.1016/j.clml.2026.06.011}
}
Kostenlos starten →